ALC - State Insurance Programs Oversight Subcommittee
November 18, 2026·11:00 AM·Room A, MAC·43:59
VideoTranscript4 documents
Summary
Machine transcript
May contain errors. Verify important quotations against the official video.
About transcript accuracy
Source
Whisper
Model
ggml-large-v3-turbo.bin
Processing date
November 18, 2026
B. Consideration for Review and Approval of Actions by the State Board of Finance 0:23
The chair, Grant Wallace, presented a comprehensive set of September 2026 pharmacy formulary changes-including brand-to-generic switches, removal of prior-authorizations for members ≤ 25, addition of a new biosimilar, and exclusions for several high-cost or weight-loss drugs-covering items 1 through 24 and related notes on step-therapy and new market drugs.
[0:42][1:15][1:52][2:28][3:01][3:32]
Subsequent motions to approve Exhibit B items were made, with Senator Irvin moving to adopt B1 (Sept 2026) and a modified B2 excluding items 7-9, and later a motion to adopt the medical drug recommendations (B3); both motions were seconded, passed without opposition, and recorded as approved.
[31:28][31:34][32:04][32:07][32:26][32:39][33:12][33:44][34:14][34:50][34:56]
We are going to call the State Insurance Program's Oversight Subcommittee of ALC to order. The first item of business, Mr. Wallace, if you want to come to the table. First items of the business are the September 2026 EBD pharmacy recommendations.
Good morning, Grant Wallace, Director of the Employee Benefits Division and Office of Property Risk. So we'll start with the September 2026 pharmacy formulary recommendations. Items one through six, we are making a change from the brand over to the generic. Items seven, eight, and nine, we are just removing the prior authorization requirements for members who are 25 years and younger. Those that are over 25 will still need to complete an appeal with the plan for coverage. Item 10, we are moving from not covering the pack, but still have the tablet formulation available for our members. Item 11 and 12, we are moving to align to the lower strength availability. In 12, we have other lower cost alternatives that are available. Item 13 is a new biosimilar that is coming on, so we are adding that to the formulary. Items 14 and 15, we are not covering because we already have lower cost generics available on our item or on our formulary. Item 16 through 18, we are moving from requiring a prior authorization to just adapting to a step therapy. So what this would mean is that you would just have to take a generic form or some other form before you step up to these particular medications. Item 19 is covering, we cover the generic tablets already, so we're not going to, we're moving away from that one of the capsule. Item 20 is a new FDA formulation for lidocaine jelly that we are adding. Items 21 through 23 are new to market drugs that we are not ready to add to the formulary as we await further studies. Item 24 is an exclusion because this is for weight loss only at this time. Items 25 through 28 are new to markets that we are not covering until we wait further studies. And then 29, this is a new to market drug that treats pancreatic cancer that has shown significant improvements in overall survival and quality of life, so we're looking to add that on to our formulary at this time. I'd be glad to pause there and answer any questions.
what is the change there? So this one, we do have lower costs, but I think there was a manufacturer change with this particular formulation, so that's why we're removing it.
you had a question yes and i just i guess i want to understand this better on seven eight and nine where we've got this age in there and obviously it looks like for acne which i assume that's a difference but i guess my my question is do we have other drugs where we have certain ages involved
reasons variety of different ages. Um, it really is depending upon what's being treated. Um, a lot of it comes down to whether you take a tablet or like a, um, a liquid, we do a lot of age restrictions on that just for swallowing and things like that. So, but what we've got, you said, tell me, tell me again, did you say you
Is that what's going on? There's some cosmetic purposes, uh, uses. So yes. Okay. And we wouldn't approve like a cosmetic, not for cosmetic purposes. Okay. I think that makes sense. Thank you, sir.
Mr. Chairman. I'm over here. Yes, sir. Um, I just had a question in the impacted members there where it talks about grandfathering. so people already on that if it says lifetime then they would have a lifetime grandfather ability and then a couple of them are 90 days why why is there a difference in that so generally
for specifically like the 90 days if we're moving from a brand to a generic we do want to give time to have the appropriate visits to the prescribing provider those kind of things to make that transition. In other areas where we kind of know that the members that are currently on it are within that particular age range, for example, there's no reason to disrupt them. We would let that continue on until obviously they've reached over the age. And then others, it's, we are trying to make a move like if we shift to a biosimilar we're okay with kind of capsulating one particular group and then try to make the new fills go on to either the new generic or the new biosimilar we try to be as least disruptive to the care as possible but at the end of the day we are trying to manage the spend and make the appropriate decisions in that way as well all right
thank you All right, members, seeing no others, I would entertain a motion for approval of recommendation. I have a motion and a second. All those in favor, let it be known
you can carry on to October. Okay, October, line number one. This is the Bez Remy pin. It's a new self-administrative version of this particular medication. We already cover this medication on the medical formulary. We're just adding this option to the pharmacy formulary just to have additional options for treatment. Item two, we already cover, this is a noodle market. We already have lower-cost alternatives available, so we're not covering it at this time. Item three is a new combination for treatment. So we are adding that just to make sure we have a good variety of treatment options for that disease condition. Items 4, 5, and 6, we are adding these back to the formulary just due to shortages of other products within this disease state. So just making sure that we don't run into any treatment issues because of that shortage. Item 7, 8, and 9, we are moving these to not covered because we already have lower cost generics available as we kind of did an evaluation of what we cover. Item 10 and 11, we are updating the quantity limits just to match to manufacturing package changes. So we didn't want to run into any issues with getting those approved. Item 12 is no longer manufactured, so we're removing that from the formulary. Items 13 through 21, we are moving from the medical benefit to add to the pharmacy benefit, and this is just aligning with giving providers flexibility in treatment. is often called white bagging where the patient would be able to go and work with their provider to get the drugs delivered to the provider's office for administration in that clinical setting. I'd be glad to answer any questions. Senator Boyd you're recognized. Thank
you Mr. Chair. So Mr. Wallace correct me if I'm wrong but I believe you said the first one and the last one are ones that are covered met by the medical benefit but you're going to allow the pharmacy benefit to cover them as well correct okay I just want to verify before we shift that is this a situation where the plans just not paying enough so we're hoping that pharmacy will eat the cost rather than somebody else no I wouldn't know this is needed to confirm as you weren't just trying to shift the problem elsewhere no sir thank you
So back with that number one, so are we saying that the pharmacy then, that these people, they can just come in on their own and they're going to get this and administer it at their house? Yes. Okay. So it's $10,421 per injection. They break their vial or whatever at the house. Who's that on?
appeal and get an early refill. But, again, there are prior authorizations with this. It is at our highest tier. So, I mean, there's an appropriate cost sharing there.
Some of those, that gets a little bit worrisome. Don't get me wrong. I want the patients to, you know, have all the benefit they can. It's just if we start getting into things like that, that does start worrying me
a little bit. No, absolutely. And it's kind of the same when you look at oral chemotherapies. I mean, dropping one pill, losing one pill can be multiple thousands of dollars. So I think there's some fine line that you want to balance to make sure that the member adheres to treatment and that we're giving them all the options available to that treatment. But at the same time, knowing that there's great responsibility that comes with those medications and making sure that the appropriate provider follow-ups and those kind of things are taking place to make sure that adherence is being maintained. Let me ask you one other
thing. So if we had one of our members, one of the patients, whatever you want to call it, if we had one of them that started having like multiple issues with like a $10,000 injection, If they had one, two, or three, do we have an avenue so that we do have an avenue so that
sure that there's no abuse or misuse or anything like that. Right. Thank you. And just a follow-up on Senator Hickey's question there. So this particular treatment is, what we're doing here is allowing us to, after it has been authorized at the medical level, to just then go fill it at the pharmacy. It's not like I can wake up one day and decide that I want to do that. It's through a treatment plan that the pharmacy, okay.
Absolutely. So the initial, any of the initials on these are done within the clinical setting. It would be the subsequent, if those are available, subsequent dosage would be done in a home setting, self-administered type setting. Thank you for that
Thank you. So explain to me on Exhibit B2 why the contraceptive and the maintenance of pregnancies are not covered. So on that particular contraceptive, we have multiple that
we do cover. This was just a new to market that we were waiting for kind of further. Didn't really see kind of a huge groundswell of adding it at this point. That's not to say later on down the road we want to, you know, swap out some and add it. We definitely can. We just felt that we have an appropriate amount that are already covered and didn't want to add that at this point. And similar to the maintenance of pregnancies, we do have a complete evaluation of what we cover. And these, we just felt we had lower cost options available that met the need at this point. but we, we will continue to evaluate. Yeah. I mean,
this worries me. I'll be honest with you because what I, what I see, and I know that I think it was Senator Bryant had a piece of legislation that just basically, as we are kind of moving down this path of, uh, legislation that requires, you know, certain things, but then insurance won't pay for it. And, but we're not keeping up with the technology and the effectiveness of maybe something that's new that's come on the mark that's really because if this is you know maintenance of pregnancy this is important stuff I mean we don't want to lose a baby we don't want to have we don't want to contribute to maternal deaths or premature babies absolutely that creates an incredible amount of expense on the back end if you have a premature baby that ends up in the NICU. And so this gives me a little bit of pause, to be frank with you. And I don't want us to have to pass legislation in order to get women what they need that's really going to be effective. And we've had to have that before. You know, we kind of get in this mindset from an insurance that, well, we're paying for a wheelchair. Well, yeah, it was built in 1950, and that's the only one we'll pay for, you know, a wooden wheelchair. Well, I think things have changed a little bit. There's some modernization here. So, you know, those things just kind of create a little bit of anxiety for me. No, I totally appreciate and understand that. Can we look at those and just try to get a little bit more information to make sure that we have something there that's sufficient?
And I know we do have stuff that's covered that is effective, And I know that we're, we're in that process of that evaluation and we're constantly wanting to make sure we're getting, um, the most effective treatment, uh, that we are managing costs at the same time. Um, and forgive me, I don't know exactly if there was kind of a, a manufacturing change or we were preferring one kind of, uh, particular maintenance drug over another. I can follow up and get you that additional information. Um, but definitely I do hear what you're saying and we do, uh, take that to heart and are kind of monitoring and making sure that we are making sure we have enough options available, but also that we are getting effective,
No, no. In this particular drug state. And then I have one more question too. Um, do you have the ability to limit pill count on high cost medication? Yes. Okay. I think that's important. Um, okay. And then the last question I have is, uh, anything as it relates to obesity and treatment of obesity, um, is that based on just the product itself or is there some sort of an exclusion that we have had that it's not considered essential health benefit therefore
we're not going to treat it? So at this time the plan excludes weight loss medications as whole on the whole. Now obviously with kind of Ozempic Majoro the type 2 diabetes diagnosis that is where those particular drugs are used to treat those disease states. Um, I think we are studying, we're evaluating, we're trying to figure out the best way. Those drugs are very expensive, um, and, and do come at a high cost for the plan. So it's, it's a hard balance. Um, and I think you'll see hopefully, um, between now and the session that we're looking at doing, um, lots of different things in order to kind of encourage healthy lifestyles within our member population, um, and looking at kind of revamping some programs, um, to really be able to work on that and combat that holistically. Um, and not just rely on a shot. I I've been on the record and will say till I'm blue in the face, there's no silver bullets to treating, um, obesity. And I want to make sure any offering that we have that is working with that is holistic. Um, and
it's also clearly being abused. I mean, you know, there's people that really are not obese that are partaking because anyway, that's a whole nother conversation. I just wanted to know if it was just how it was considered and if
it was okay. Thank you. Thank you. And in following up from that, uh, Mr. Rawls, would you mind just, uh, send to staff kind of what the alternatives are in that class for the maintenance of pregnancy. And if there's a wide variation of insert or use, so if one, you have, it's $5, but you have three times as many applications. If they're all relatively the same, then you don't have to give that, just the cost is fine. but that would be helpful to follow up with Senator Irvin's question. Okay. All right. Senator Hickey, you have a question you recognize? Yes. I keep, and
I don't have an answer for it. I just hate to keep harping on it. And there's a whole bunch of these. I used number one first, but let's just go to number 21. So that particular one is $17,000 per injection. So when we're allowing them to go to the pharmacy and to get this, and it looks like there's four injections per month are we allow are we allowing them to pick up this thing which would
be six a sixty eight thousand dollar cost for us for a month so the ones that are 13 through 21 are still going to be administered in a clinical setting by a provider this is just allowing a different kind of reimbursement and a different access for that patient some providers don't want to stock medications don't want to have to like manage the quote-unquote pharmacy benefit so this allows another path for the member to be able to access that but at the end of the day the drug is still being ministered in a clinical setting under the purview of a provider perfect on that
one so let's go back to number one so and i have no idea so on on this number one ten thousand four hundred and twenty one dollars per injection like how many times a month would that one be i wonder it's i guess i guess the thing is is i'm i'm looking at it like on your last one that is in a clinical setting i just i don't know if this is once a week or if this is ever two or three days are we are we dispersing this to go to the house where it's going
so the one um i believe is just every 30 days and that that is the self like i would be able to administer that to myself after i've done the initial treatment and then have been trained on how to do it through with a provider but we
are monitoring those so that we're not i mean i don't know where there's a where there's a stopping point you know and again i understand if you're if you've got that problem and you want to be at home but there does get to be a point right there if you let's just use the last one and again you have that in a clinical setting you know if something gets up to a certain amount of money are we looking at it that it still has to be in that clinical setting
to be administered so and again it's going to depend upon the certain drug which one is going where but we are monitoring the spend and we are making sure you know if there is a high cost claim or anything like that that that it is being reviewed and that there are kind of the appropriate stops that there's no early refills or anything like that right
just just point blank so you got got one that's 10 000 a month if it's 10 000 a month maybe that's appropriate you know it's just if they're keeping this in the refrigerator or whatever and you got grandkids or whatever that can get to it i just assumed that there has to be a point right there i wouldn't want the 68 000 when us to ever do something that was 68 000 you know that was we didn't have some safeguards in in place because you start talking about six 68 000 a month for 12 months you start talking about some real money yes
sir so and i do want to correct one thing they're letting me know so the pin is actually uh two times a month uh so it's dosed every two weeks um it says oh okay that's the top one yeah tier four is the specialty tier so that has the highest copates to it and again that prior authorization does protect the plan that we're making sure that this is an appropriate member um that is in the setting to be able to um do this at home okay i think you
know where i'm kind of going with this stuff it just there looks like to me there has to be at some point at some point on whenever we're looking at stuff like that it just has to be at some point i think where we really have to study whether or not we should allow those at home or if it has to be in the clinical
setting so right okay thank you sir thank you and senator ervin they did give me some additional information on seven um and eight the endometrin that's the name brand so we do have the generics um in that one so that that's what's going on there senator
ervin you recognized and generics don't always work great and they and so everybody is different absolutely and so i i really i really would love for us to cover these because it's it doesn't seem like it's a huge amount of cost but um can i just request that y'all really take a strong look at that absolutely because a generic it's yes sometimes that will work but sometimes it won't no absolutely we just I want to make sure that if if a doctor says she needs this and this is going to maintain this pregnancy to create a two-term delivery then we need to spend the money to do that period point blank because preventing a premature birth to me is worth its weight and galt absolutely so those those three seven eight and nine i would really prefer that we do cover them somehow some way senator ervin are you recommending
i i do i would the contraception one i know i understand that one but when we're talking about maintenance of pregnancy issues and endometriosis and i mean and the progesterone vaginal insert whatever we've got to give that doctor the tools that they need right then and there to really make sure that we're maintaining that woman's pregnancy to term that's very very very important absolutely so yeah i would pull these three off and have you guys try to really okay do some more hard look here because i'd love to have them covered if we need to have a prioritization of course but we i need to know more about this absolutely i really would prefer them to be covered thank
you mr chair thank you senator ervin so if you would just that analysis of what all the options are the generics and and other name brands potentially or whatever and send that to staff and then we can we can address this at the next uh at the next meeting okay all right
senator boyd you're recognized thank you mr chair so going back to number one, the Bezrimi. Just for clarity's sake, would you say that that comes in a pen, which while it could be broken, is harder to break than just a regular glass vial? Yes, sir. Thank you, sir. And then would you also agree that if the patient is administering it as opposed to taking it to a clinic, that might avoid some administration charges that need to be considered in the overall scope of things? Yes, sir. Okay. Thank you for
to get in on this discussion. First of all, back to what Senator Boyd says in regards to self-administration. Because the conversation was about getting refilled early if a valve breaks or whatever. How often does that happen? How often does this occur? Not very often. And they would
come to us for an exclusion or an override. So, I mean, it has to be pretty extreme circumstances. The ones that I have personally dealt with have been as a result of the winter storm, That came through and lost power and
I would have to go back and run that. It's not significant to the overall plan spin. I think if I'm kind of understanding where you're going with the question, this is not a huge aspect of what we're dealing with. There are very rare instances where we would authorize an override due to power outage or damage in shipment or something
like that. Okay. All right. Thank you. And then the second thing in regards to what Senator Irvin was saying, because I've actually, I personally have not experienced this, but I've actually had this experience. Are we just looking at those, taking off those drugs, 789, just because we have generic versions, or is it cost-saving? Like, what are we, what's the overall piece that we're trying to get to? It
was to prefer kind of the generic, which is at a lower cost in comparison to the name brand. But we're going to go back, do that overall study, and bring it back
to you all at a later date. Okay. All right. Yes. I truly appreciate Senator Irvin, what she was expressing, because I've definitely heard this, and I've actually experienced this. Well, not personally, but I've experienced it. So thank you. Thank you, Senator Irvin, and thank you, Mr. Chair. all
right representative back you had a question yes thank you this kind of follows up on senator hickey's maybe one of his concerns but in a little different mix so a drug like that you know has a ten thousand dollar would we just how many would we get four doses my point is this if this drug requires refrigeration are we putting it in a you know there are refrigeration systems that are backed up and have been a power loss do we ever consider like if you had 10 of these doses sitting in a in the personal fridge rather power goes out now you've
so no i mean they there would not be excess dosage that some is sitting at somebody's home i mean that you're going to look at probably getting refills on a monthly you know if this is a every other week kind of dosage we're only going to give them two two pins that they would be storing and then they would go back the next month
Irvin would you make your motion thank you Mr. Chair yes so I make a motion to approve let's see B1 I will make a motion to approve all of B1 September 2026 it's b2 yes i know but we have to approve b1 and b3 as is b2 would be without seven eight nine so we already approved b1 though oh you are i'm so sorry okay my my apologies so b2 would be to approve with uh without seven eight nine
included all right so we have a motion do we have a second second we have a motion and a second to any discussion if not all those in favor let it known by aye aye any opposed motion carries now we will move on
to item number three which is the medical drug recommendations b3 all right starting with b3 these are again disclaimer drugs that are administered in a clinical setting items one and two are new to market we're going to exclude as we await further studies item three and four and five are all related to that disease state but we are item three and four are the biosimilar that we are looking to add item five would be the name brand that we are going to exclude moving forward item six we're excluding as news to market and looking for ongoing studies on that one Item seven and eight are related. We are going to cover the item seven. This one's new to market, but is outperforming number eight. It takes fewer injections and has a better overall outcome for the patient. Item 9 and 10, these are adding on as new trials have shown better overall survival. Item 11 is a new-to-market cancer-treating drug, but it has already achieved the national cancer rating of Category 1 and has obviously proven better outcomes and better overall survival rates, so we're looking to add that one on. And then item 12 is an Alzheimer's disease drug that we've been studying for quite a while, and we are adding Consumla to our formulary as it aligns with Blue Cross, their treatment criteria, as well as it gives us just a little bit more control with fixed dosage, does have the potential to stop after one year if the plaques have been cleared. So I'd be glad to pause and answer any questions related
to these drugs. Okay, members, any questions? If not, then I would entertain a motion to approve the recommendations. I have a motion. I have a second. Any discussion? If not, all those in favor, let it be known by aye. Aye. Any opposed? Motion carries. Seeing no other business.
Sure. And maybe this is for the chairs for us to consider. kind of based on the conversation right here and kind of what Senator Love had brought up would would you all mind kind of giving us a breakdown over the last year or the last two years that how much you know with some of these drugs how much of it has went bad how many of you had to come back and get and I don't know if we should start it should look at and consider that maybe there's a cost cap on how much we'll allow allow for month before it needs to go to a clinical setting some of these things and i assume we had never would but and i see some of them that you're turning down you're talking about you know 140 000 per dose i assume there's going to be at some point where we would not allow those to be administered or kept at the house but i just want to know what the cutoff is the one that we were just discussing with that number one that's twenty thousand dollars a month is that our cap or is it fifty or is it a hundred or what are do
we have any type of cap in place so it's not necessarily really a financial cap we are following fda kind of recommendations and guidelines as we look and and that's when it comes through is when there's new guidelines issued or new formulations that kind of go through all of those review and approval processes that's really what is driving whether it's kind of in that home or appropriate for a home kind of kind of kind of setting but we definitely can kind of look and evaluate what would be an appropriate kind of gauge on misuse and when we would need to remove that authorization or that approval for that particular member i we can go back and study that i'm just not sure for our plan though if
and i appreciate what you said about the fda i'm just not for sure for our plan that if we should look at and maybe the membership here doesn't agree that at some point if if if a drug is a certain dollar amount per month again that maybe it should be administered in some type of clinical uh setting maybe there's some time you know that you would look that there could be some exceptions on that with with the cost of some of these like I say I do worry because even the one that we're talking about we're talking about over 20,000 a month you know for somebody to have and again maybe the committee doesn't agree with me on this and that's fine I just uh I at least think it's worth the conversation to see if we should put something lockhead in. Yes, sir. Thank you. Senator Boyd, do you recognize? Thank you, Mr. Chair. Mr. Wallace,
this is not to disagree with Senator Hickey. This is, again, to try to add a little clarity. If we're going to look at, hey, is there a dollar amount we're concerned about, we would also want to look at what that might cost in administration fees or other things so that we just feel like we're making a good sound decision, you know, because the point is well taken, you know, somebody loses $100,000, it's going to take a lot of trips to the doctor to save $100,000. But also, you know, I know it's hard to go find an example of one of these, but they are hard to break, but it could happen, right? So if you can help give the whole story, that would be helpful
to all of us. Thank you. And just one last follow up on that. In some cases, and I don't know in this situation we've been talking about mostly today, it probably, if you can determine this, it probably makes sense to do it via pharmacy like we're talking about because of the availability of the doctors or the clinics to actually administer it. So if, if there's some problem in the system that says that for, you know, this doctor visit or this cancer treatment, it's just easier or better or more timely because of that, just any, any kind of background so we can make a fully informed decision would be helpful. Okay. Senator Irvin. Yeah. Thank you.
I think it's a good conversation to have. And that's one of the reasons why I asked about pill count, right? Because if you have the ability to, because a lot of these medications are expensive. I mean, even if they're not, I think a lot of times, and we have done this on certain, you know, schedules of drugs to try to limit the amount of pills out there, right? So for various reasons, because they're being sold on the block market or whatever. But, you know, it's a difference between I give myself a B12 injection shot every week, which I can administer with a syringe and a glass vial versus because it's not that expensive versus and I'm referring to my father. And so versus something that, you know, costs $11,000, like I would have a heart attack with that were in my refrigerator because it may get lost or whatever. I think there is credibility to discuss this and to try to figure out a way. I know specialty pharmacies, my dad's on a specialty pharmacy medication, and they call every single month and I have to authorize this because we don't want something to be wasted. We don't want money to be wasted. We don't want medication to be wasted or lost or misused or whatever. So I think it's a worthy conversation to have for sure and just to figure out what makes sense, you know, what's
common sense about it. And absolutely, and kind of to your point on kind of pill limits or anything like that, I mean, a lot of the oncological drugs that are kind of coming in and being able to be administered outside of the clinical setting do have quantity limits, do have half fills, do have all of those kind of guidance that you've kind of mentioned in place so that we can control that cost. So absolutely, I hear and agree, we'll give all the background and kind of be able to paint kind of a picture of what's
was a good conversation. Thank you. And just to follow up, because Senator Durbin brought up a good point, I was under the assumption that what we were talking about earlier was that it was administered at the pharmacy and they were maintaining it. These are going picked up at the pharmacy and going home with them. So I assumed it was like the farm, the, uh, flu shot or, or some of the other vaccinations. These are actually going home. All
right. Thank you for that clarification. And I just to clarify a little bit more, because there are some that are being filled at a pharmacy location, but then being sent over to a clinical provider for administration in that setting too. So you've kind of got the three, four different kinds of scenarios going on there. Good, good conversation. All
Thank you for, thank you, Mr. Chair. So again, to add to the conversation, not to track from any other questions, for the most part, all of these medications we're talking about sending home, the FDA has created a package a way for where they've evaluated and said this is safe for the patient to self-administer number one yes sir number two would you not agree that a physician or a nurse practitioner or a physician assistant someone with prescriptive authority has had the opportunity to evaluate whether or not that makes sense in that that case so if someone has significant alzheimer's and they don't you know have a caregiver probably we're going to bring them back we're going to find a way to get them back to the clinic or what have you would you agree yes sir okay thank
B. Consideration for Review and Approval of Actions by the State Board of Finance
0:23 - 35:19125 segments16 speakers
The chair, Grant Wallace, presented a comprehensive set of September 2026 pharmacy formulary changes-including brand-to-generic switches, removal of prior-authorizations for members ≤ 25, addition of a new biosimilar, and exclusions for several high-cost or weight-loss drugs-covering items 1 through 24 and related notes on step-therapy and new market drugs.
[0:42][1:15][1:52][2:28][3:01][3:32]
Subsequent motions to approve Exhibit B items were made, with Senator Irvin moving to adopt B1 (Sept 2026) and a modified B2 excluding items 7-9, and later a motion to adopt the medical drug recommendations (B3); both motions were seconded, passed without opposition, and recorded as approved.
[31:28][31:34][32:04][32:07][32:26][32:39][33:12][33:44][34:14][34:50][34:56]